A patient receives a drug that selectively activates muscarinic ACh receptors in the heart. What effect would you predict on heart rate, and why does this differ from the effect of nicotinic receptor activation?
AHeart rate increases, because ACh is excitatory at all its receptors
BHeart rate decreases, because muscarinic M2 receptors open potassium channels that slow the pacemaker — unlike nicotinic receptors, muscarinic signaling can be inhibitory
CHeart rate is unchanged, because muscarinic receptors in the heart are non-functional
DHeart rate increases briefly then decreases, because muscarinic receptors are ionotropic and cause a fast excitatory burst followed by inhibition
Muscarinic receptors are metabotropic (G-protein coupled) and their effect depends on receptor subtype and tissue. In the heart, M2 receptors couple to Gi, which opens inward-rectifier K⁺ channels, hyperpolarizing the pacemaker cells and slowing heart rate. This is the exact mechanism Loewi demonstrated in 1921. Nicotinic receptors, by contrast, are ionotropic ion channels that depolarize the membrane and are always excitatory. The key insight is that the receptor type, not the transmitter, determines the effect.
Question 2 Multiple Choice
Exposure to an organophosphate nerve agent causes muscle paralysis, excessive gland secretion, and dangerous slowing of the heart simultaneously. Which feature of the cholinergic system explains why a single agent affects all these systems at once?
ANerve agents are broad-spectrum toxins that non-specifically damage all neural tissue
BACh is the neurotransmitter at all preganglionic autonomic neurons, all parasympathetic postganglionic neurons, and the neuromuscular junction — so blocking AChE affects all cholinergic synapses throughout the body
CNerve agents block nicotinic receptors selectively, and nicotinic receptors are present throughout the peripheral nervous system
DThe autonomic and somatic nervous systems share the same synaptic vesicles, so a single toxin can affect both
Organophosphates inhibit acetylcholinesterase (AChE), causing ACh to accumulate at every cholinergic synapse. Because ACh is used at the neuromuscular junction (muscular effects), all autonomic preganglionic synapses (both sympathetic and parasympathetic), and parasympathetic postganglionic synapses (cardiac, glandular, smooth muscle effects), a single AChE inhibitor affects the entire peripheral nervous system simultaneously. This broad distribution is a key anatomical feature of the cholinergic system.
Question 3 True / False
Acetylcholine generally produces excitatory effects because it is the neurotransmitter at the neuromuscular junction, which causes muscle contraction.
TTrue
FFalse
Answer: False
This is the core misconception about the cholinergic system. ACh's effect depends entirely on the receptor it binds. At nicotinic receptors (including the NMJ), ACh is excitatory via fast ionotropic signaling. At muscarinic receptors, ACh can be inhibitory — the classic example is M2 receptors in the heart, where ACh slows heart rate. The transmitter does not determine excitation or inhibition; the receptor type and the G-protein it couples to determine the effect.
Question 4 True / False
Donepezil (an Alzheimer's drug) works by directly replacing the acetylcholine lost due to basal forebrain neuron degeneration.
TTrue
FFalse
Answer: False
Donepezil is an acetylcholinesterase inhibitor — it works by blocking the enzyme that breaks down ACh, thereby prolonging the action of whatever ACh the remaining neurons still release. It does not replace lost neurons or synthesize new ACh. This is a symptomatic treatment that compensates for reduced ACh by slowing its degradation, not by restoring the degenerated cholinergic projections from the basal forebrain.
Question 5 Short Answer
Explain why the same neurotransmitter (ACh) can produce both fast muscle contraction at the neuromuscular junction and slow heart rate reduction in the cardiac pacemaker, and what determines which effect occurs.
Think about your answer, then reveal below.
Model answer: The effect of ACh depends on the receptor type present in the target tissue, not the transmitter itself. At the NMJ, ACh binds nicotinic receptors — ligand-gated ion channels that open immediately upon binding, allowing Na⁺ influx and causing fast membrane depolarization and muscle contraction. In the cardiac pacemaker, ACh binds muscarinic M2 receptors — G-protein coupled receptors that activate intracellular signaling cascades, ultimately opening K⁺ channels that hyperpolarize the cell and slow pacemaker firing. Same transmitter, opposite effects, because the receptor class determines the mechanism.
This principle — that the postsynaptic receptor, not the neurotransmitter, determines the nature of the signal — is fundamental to neuropharmacology. Many drugs work by targeting specific receptor subtypes, exploiting this receptor-specificity to produce effects in one tissue (e.g., heart) without affecting another (e.g., skeletal muscle). Understanding ACh's dual receptor system makes the logic of many cardiovascular and neurological drugs immediately clear.